

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10825580
Filing Date	2004-04-15
First Named Inventor	Anja Kohlrausch
Art Unit	1614
Examiner Name	M. R. Finn
Attorney Docket Number	01-1491

U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S.PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add		
NON-PATENT LITERATURE DOCUMENTS						Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10825580
	Filing Date		2004-04-15
	First Named Inventor		Anja Kohlrausch
	Art Unit		1614
	Examiner Name		M. R. Finn
	Attorney Docket Number		01-1491

	1	Freytag, F., et al- Telmisartan, Hypertension Experience in a Randomized European Study... pgs 108-23	<input type="checkbox"/>
	2	Lacourciere, Y. A new Fixed-dose Combination for Added Blood Pressure Control; pgs 366-379	<input type="checkbox"/>
	3	Neutel, J.M., et al; Long Term Efficacy and Tolerability of Telmisartan as Monotherapy... gs 302-309	<input type="checkbox"/>
	4	Richter A., et al; Mild to Moderate uncomplicated hypertension ; Further Analysis of a cost effectiveness study of live drugs. pgs 61-69.	<input type="checkbox"/>
	5	Scarpa, William J., Micardis/HCT(telmisartan/hydrochlorothiazide) New Therapy update; Journal of Clinical Hypertension Vol. 3, No. 4, July/August 2001	<input type="checkbox"/>
	6	Wienen, W., et al; Effects of Telmisartan, Hydrochlorothizaide and their combination on blood pressure and renal excretory parametersin spontaneously hypertensive rats	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.